Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human alkaline phosphatase - AMRIF/CEVEC

Next Previous
Drug Profile

Recombinant human alkaline phosphatase - AMRIF/CEVEC

Alternative Names: hRESCAP; Recombinant human placental alkaline phosphatase; rhuAP; rhuAP-CAP cell; Theraptech project

Latest Information Update: 10 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alloksys Life Sciences; CEVEC Pharmaceuticals
  • Developer AMRIF; CEVEC Pharmaceuticals
  • Class Anti-inflammatories; Anti-ischaemics; Hepatoprotectants; Phosphoric monoester hydrolases; Recombinant proteins
  • Mechanism of Action Cytokine modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 06 Oct 2022 CEVEC Pharmaceuticals has been acquired by Cytiva
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Netherlands (Parenteral)
  • 13 Jan 2014 Recombinant human alkaline phosphatase - AMRIF/CEVEC is available for licensing. http://www.alloksys.com

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top